Enanta Pharma (ENTA) Misses Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SPY
9. SWKS
10. FISV

Go back to Enanta Pharma (ENTA) Misses Q4 EPS by 2c

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

November 21, 2022 4:02 PM EST

Initiated SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 Study of EDP-235, an Oral, 3CL Protease Inhibitor, in Non-Hospitalized, Symptomatic Patients With Mild to Moderate COVID-19 Initiated RSVHR, a Phase 2 Study of EDP-938, an Oral N-Protein Inhibitor, in Adults at High Risk for Complications from Respiratory Syncytial Virus (RSV) Began Dosing in a Phase 1 Study of EDP-323, a Novel, Oral L-Protein Inhibitor Designed for the Treatment of RSV Royalty Revenue for the Quarter was $20.3 Million

WATERTOWN, Mass.--(BUSINESS... More